In farming districts across Peru, where fields of potatoes, corn, and quinoa stretch across highland valleys, residents are exposed to dozens of agricultural pesticides simultaneously. A study published in April 2026 in Nature Health now quantifies what that exposure may cost them: people living in the most pesticide-heavy areas showed cancer rates up to 150% higher than those in the least-exposed parts of the country, with liver and stomach cancers driving the sharpest increases.
The research, led by scientists from France’s Institut de Recherche pour le Développement (IRD), Institut Pasteur, the University of Toulouse, and Peru’s National Cancer Institute (INEN), is the first national-scale attempt to map the cancer burden tied not to a single chemical but to the combined load of many pesticides acting together. Its findings land at a moment when agricultural expansion across Latin America, sub-Saharan Africa, and South Asia is outpacing the regulatory frameworks meant to protect the people who live closest to the fields.
What the researchers found
The team built an exposure model covering 2014 through 2019 that estimated environmental concentrations of 31 agricultural pesticides across Peru’s territory. They then overlaid those estimates onto geocoded cancer cases from the INEN national registry, which spans 2007 to 2022. Districts with the highest modeled pesticide-mixture concentrations showed significantly elevated rates of liver and stomach cancer compared to low-exposure districts. The researchers describe their approach as “spatial exposomics,” a term they use for a method that fuses environmental modeling with disease mapping to estimate risk at a fine geographic scale.
The 150% figure represents the upper bound of that spatial association, observed in the most heavily exposed rural districts when comparing district-level cancer incidence between the highest and lowest modeled mixture-exposure zones. The study does not specify whether this metric is an incidence rate ratio, odds ratio, or another measure of relative risk, and no confidence interval for the figure is provided in the available summary. It does not mean every person in those areas will develop cancer. Rather, it indicates that populations in the highest-exposure zones carry, on average, a substantially greater burden of certain cancers than comparable populations elsewhere in Peru.
Biomonitoring backs up the models
A key question with any modeled exposure estimate is whether it reflects what people actually carry in their bodies. Separate biomonitoring research conducted in Peru’s Central Andes offers a partial answer. In that study, published in Scientific Reports, scientists measured 170 pesticide compounds and metabolites in blood and urine samples from residents of high-altitude farming communities. Among the compounds detected were the neonicotinoid insecticide imidacloprid and the triazole fungicide tebuconazole. The Scientific Reports paper reported that concentrations of several detected pesticide groups in Andean participants were higher than levels documented in general-population biomonitoring surveys conducted in European and North American settings, though the paper did not provide a single summary magnitude for the difference across all compounds.
Those results serve as a real-world check on the Nature Health study’s modeled estimates. People in Peru’s agricultural zones are not just theoretically exposed. They carry measurable pesticide residues consistent with intensive, season-after-season application.
Why mixtures matter more than single chemicals
Most pesticide safety standards worldwide are set one active ingredient at a time. A chemical is tested in isolation, assigned a threshold, and regulated accordingly. But farmworkers and rural residents are rarely exposed to just one compound. They encounter complex cocktails that shift with the growing season.
An animal experiment published in Communications Biology explored what those cocktails do at the cellular level. Researchers exposed rats to low-dose pesticide mixtures and observed significant metabolic disruption in the gut and liver, including altered signaling and detoxification activity linked to cancer-related pathways. Critically, these effects appeared even when individual pesticide components fell below the doses considered harmful on their own.
Liver cells were especially affected, displaying changes consistent with nongenotoxic carcinogenesis, a process in which cancer is promoted not by direct DNA damage but by chronic metabolic stress that primes tissues for tumor growth over time. This finding is central to the Nature Health paper’s argument: the danger may not come from any single chemical but from the combined burden of many chemicals acting on shared biological pathways in organs that process toxins.
What the study cannot tell us
The Peru analysis relies on spatial associations, not individual-level tracking. Researchers matched geographic pesticide estimates to cancer registry data across districts, but they did not follow specific people over time to record personal exposure and subsequent diagnoses. That distinction matters. Spatial correlation can reflect shared geography, poverty, diet, or healthcare access rather than a direct chemical cause. Farming regions may also have lower cancer screening rates, different viral infection patterns (hepatitis B and C are major liver cancer drivers), or distinct dietary habits that independently influence liver and stomach cancer risk.
The biological mechanism also remains partially open. While the rat study demonstrated metabolic disruption consistent with nongenotoxic carcinogenesis, other toxicology work has found that certain pesticide combinations, including some involving imidacloprid and tebuconazole, can demonstrate genotoxicity when tested together. Whether the dominant pathway in exposed Peruvian populations is genotoxic, nongenotoxic, or some combination has not been confirmed in human tissue samples.
The exposure model itself stops at 2019, leaving a gap of several years before publication. Pesticide use patterns, crop types, and regulatory enforcement in Peru may have shifted during that interval. Without an updated national model, it is unclear whether current risk is higher or lower than what the study captured.
Cancer registry data in low- and middle-income countries can also miss cases, particularly in remote rural areas where access to oncology services is limited. If underreporting is more severe in some districts than others, apparent differences in cancer incidence could partly reflect health system gaps rather than true variation in disease. The Nature Health analysis attempted to adjust for some of these factors, but residual bias cannot be ruled out.
The regulatory gap
Peru regulates pesticide use through SENASA, its national agricultural health authority, which approves active ingredients and sets application rules. But like most regulatory bodies worldwide, SENASA evaluates chemicals individually. The Nature Health study’s core implication is that this one-at-a-time approach may systematically underestimate risk for populations exposed to overlapping chemicals season after season.
That gap is not unique to Peru. The European Food Safety Authority (EFSA) has acknowledged the challenge of cumulative risk assessment for pesticide mixtures but has only begun piloting mixture evaluations for a limited number of chemical groups. In the United States, the Environmental Protection Agency’s cumulative risk framework covers certain organophosphates but does not extend to the full range of mixtures found in real agricultural settings. For countries with fewer regulatory resources, the challenge is even steeper.
Several of the pesticides flagged in the Peru research, including imidacloprid, face restrictions in the European Union due to concerns about pollinator health, though they remain widely available in many Latin American and Asian markets. The question of whether human health risks should trigger similar restrictions is one the Nature Health findings push squarely into view.
What communities and policymakers can do now
For people living or working in agricultural regions, the practical signal from this research is specific: the strongest risk associations involve liver and stomach cancers and appear tied to mixtures rather than any single pesticide. That specificity points toward targeted action rather than generalized fear.
At the community level, practical steps include advocating for stricter buffer zones between fields and homes, better protective equipment and training for farmworkers, and enforcement of application rules that limit spraying near water sources and populated areas. Public health authorities can prioritize targeted screening and early detection programs for liver and stomach cancers in the districts the Nature Health analysis identified as most heavily exposed.
The biomonitoring methods used in the Central Andes study offer a model for personal exposure assessment, though such testing is not yet widely available outside research settings. Expanding access to biomonitoring in high-exposure communities would help bridge the gap between modeled estimates and individual risk.
For policymakers, the study strengthens the case for moving toward cumulative risk assessment frameworks that evaluate pesticide mixtures as they actually occur in the environment, not as isolated compounds in a laboratory. That shift would require new data infrastructure, updated toxicological testing protocols, and political will to confront the economic interests tied to current agricultural practices.
How to weigh the 150% figure
The 150% figure is striking, and it should be taken seriously. But it describes the upper end of a spatial association in the most heavily exposed districts, not a universal sentence for everyone in Peru’s countryside. The Nature Health paper does not specify the exact statistical metric behind the number or provide a confidence interval in its publicly available summary, which means readers should treat it as an approximate upper-bound estimate rather than a precise risk multiplier. The signal is strong enough to justify precautionary action and sustained research investment, even as key questions about causality, mechanisms, and current exposure levels remain open. What the evidence does not support is waiting for perfect data before acting. The convergence of modeled exposure, biomonitoring, and experimental toxicology points in one direction, and the populations bearing the highest burden are the ones with the least power to demand change.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
